UPDATE: H.C. Wainwright & Co. Initiates Coverage on Prana Biotechnology Limited with Buy Rating, $20.50 PT Ahead of Results Announcement

Loading...
Loading...
In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on
Prana Biotechnology LimitedPRAN
with a Buy rating and $20.50 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Prana Biotechnology Ltd. with a BUY recommendation and a $20.50 one-year price target. In our view, two ongoing randomized, double-blind Phase IIa trials of Prana's lead drug candidate, PBT2, in Huntington's and Alzheimer's diseases (HD and AD, respectively) are likely to deliver favorable results soon. We note that Prana was granted a trading halt on the Australian Securities Exchange yesterday (Feb. 17) due to a pending announcement of top line results of its HD trial, called Reach2HD. The results are likely to be announced today or tomorrow. Prana guided to announcing top line results of the AD trial, called IMAGINE, in mid-March.” Prana Biotechnology Limited closed on Friday at $7.25.
Posted In: Analyst ColorInitiationAnalyst RatingsGeorge B. ZavoicoH.C. Wainwright & Co.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...